ArticleJournal of neuro-oncology2018

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Phioanh Leia Nghiemphu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.